PD62-11 PATHOLOGIC STAGE AS A SURROGATE FOR ONCOLOGIC OUTCOMES AFTER RECEIPT OF NEOADJUVANT CHEMOTHERAPY FOR HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA

Nirmish Singla,Alana Christie,Timothy N. Clinton,Yuval Freifeld,Rashed Ghandour,Solomon L. Woldu,Firas Petros,Wei Qiao,Haley Robyak,Aditya Bagrodia,Yair Lotan,Jay D. Raman,Surena F. Matin,Vitaly Margulis

PD62-11 PATHOLOGIC STAGE AS A SURROGATE FOR ONCOLOGIC OUTCOMES AFTER RECEIPT OF NEOADJUVANT CHEMOTHERAPY FOR HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA

2019

Nirmish Singla
Alana Christie
Timothy N. Clinton
Yuval Freifeld
Rashed Ghandour
Solomon L. Woldu
Firas Petros
Wei Qiao
Haley Robyak
Aditya Bagrodia
Yair Lotan
Jay D. Raman
Surena F. Matin
Vitaly Margulis

INTRODUCTION AND OBJECTIVES:Oncologic benefits of neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC) have been described. The prognostic significance of pT0-1 stage in patie...

Keywords:

Oncology
Receipt
Urology
Pathologic stage
Carcinoma
Chemotherapy
Internal medicine
Medicine
urothelial carcinoma
upper tract

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations